Misplaced Pages

Richard Barker (businessman): Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 04:37, 8 July 2024 editCherif Lot (talk | contribs)6 editsm Correcting typos and making minor changesTags: Visual edit Disambiguation links added Newcomer task Newcomer task: copyedit← Previous edit Revision as of 20:27, 25 August 2024 edit undoProf Richard Barker (talk | contribs)4 edits Updated Richard Barker's career details, including his current and past board memberships, and added his role as a visiting professor at King's College London. Adjusted references and formatting for accuracy.Tags: Reverted possible BLP issue or vandalism COI template removed references removed Visual edit: SwitchedNext edit →
Line 1: Line 1:
{{Short description|British healthcare consultant}} {{Short description|Healthcare leader and precision medicine expert}}
'''Prof. Richard Barker''' {{post-nominals|country=GBR|OBE|FFPM}} is a ] leader known for his forward-thinking approach and innovative contributions to the field. He co-founded and chairs Metadvice<ref>{{cite web |title=Metadvice |url=https://www.metadvice.com/ |access-date=2024-08-25}}</ref>, a company developing AI-driven healthcare platforms. He also established New Medicine Partners<ref>{{cite web |title=New Medicine Partners |url=https://newmedicine.io/ |access-date=2024-08-25}}</ref> and is the Founding Director of the ]’s ]<ref name="CASMI">{{cite web |title=Dr Richard Barker OBE |url=http://casmi.org.uk/dr-richard-barker/ |url-status=dead |archiveurl=https://archive.today/20130423193417/http://casmi.org.uk/dr-richard-barker/ |archivedate=2013-04-23 |accessdate=2013-02-11 |publisher=CASMI}}</ref> in collaboration with University College London. Barker is the chair of the advisory board at NWPharmaTech<ref>{{cite web |title=NWPharmaTech |url=https://nwpharmatech.com/ |access-date=2024-08-25}}</ref> and a co-founder and board member of 2BWell<ref>{{cite web |title=2BWell |url=https://www.2bwell.org/ |access-date=2024-08-25}}</ref>, a mental health initiative supporting Ukrainians. Additionally, he is a visiting professor in Precision Population Health at King’s College London.
{{Advert|date=July 2020}}

'''Richard William Barker''' {{post-nominals|country=GBR|OBE|FFPM}} is the Founder of New Medicine Partners and Founding Director of the ] — University College of London ] (CASMI).<ref name=CASMI>{{cite web|title=Dr Richard Barker OBE|url=http://casmi.org.uk/dr-richard-barker/|publisher=CASMI|accessdate=2013-02-11|url-status=dead|archiveurl=https://archive.today/20130423193417/http://casmi.org.uk/dr-richard-barker/|archivedate=2013-04-23}}</ref>



{{Infobox person {{Infobox person
| name = Richard William Barker | name = Prof. Richard Barker
| occupation = Life Sciences and Healthcare leader | occupation = Healthcare Leader and Precision Medicine and Longevity Expert
| known_for = Founder of New Medicine Partners and Founding Director of the University of Oxford. | known_for = Founder of New Medicine Partners, Co-founder of Metadvice, and Founding Director of the University of Oxford’s Centre for Sustainable Medical Innovation. Chair of the Advisory Board at NWPharmaTech and a leader in advancing precision medicine, healthcare innovation, and healthy longevity initiatives.
}} }}


== Early life == == Early life ==
Barker was born in South ] prominent family relatives such as Araminta march socialite, ''Mr.'' Clifford Barker a former Philip green associate and Kia Harriette his only child. He attended ]<ref>{{Cite web|title=Home - Alleyn's School|url=https://www.alleyns.org.uk/|access-date=2021-10-05|website=www.alleyns.org.uk|language=en-US}}</ref> in ]. Barker was born in South ] and attended Alleyn's School<ref>{{Cite web|title=Home - Alleyn's School|url=https://www.alleyns.org.uk/|access-date=2024-08-25|website=www.alleyns.org.uk|language=en-US}}</ref> in Dulwich, London.


== Higher education ==
Barker was educated at ],<ref>{{Cite web|title=Homepage|url=http://www.exeter.ox.ac.uk/|access-date=2021-10-05|website=Exeter College|language=en-GB}}</ref> where he received a ] in chemistry. Following completion of his degree, he researched biological applications of ]s in pursuit of an Oxford<ref>{{Cite web|title=University of Oxford|url=https://www.ox.ac.uk/|access-date=2021-10-05|website=www.ox.ac.uk}}</ref> ] degree, followed by post-doctoral studies in ] and ].<ref>{{Cite web|url=http://www.hm.edu/en/|title=Munich University MUAS - HM Hochschule München University of Applied Sciences}}</ref><ref>{{Cite web|last=Leeds|first=University of|title=University of Leeds|url=https://www.leeds.ac.uk/|access-date=2021-10-05|website=www.leeds.ac.uk|language=en}}</ref>


==Career== == Education ==
Barker studied chemistry at ],<ref>{{Cite web|title=Homepage|url=http://www.exeter.ox.ac.uk/|access-date=2024-08-25|website=Exeter College|language=en-GB}}</ref> earning a bachelor's degree. He pursued research on the biological applications of ] for his PhD in Philosophy at ], followed by post-doctoral studies in Munich, Germany, and ], England.
Barker's business career has included work in both Europe and the US.<ref name=Bloomberg>{{cite web|title=Richard W. Barker D.Phil., B.A., M.A.|url=http://investing.businessweek.com/research/stocks/people/person.asp?personId=436430&ticker=ICO:CN&previousCapId=23112550&previousTitle=ICO%20THERAPEUTICS%20INC|publisher=Investing.businessweek.com|accessdate=2013-02-11}}{{dead link|date=April 2023|bot=medic}}{{cbignore|bot=medic}}</ref> He worked for ]<ref>{{Cite web|title=McKinsey & Company {{!}} Global management consulting|url=https://www.mckinsey.com/|access-date=2021-10-05|website=www.mckinsey.com|language=en}}</ref> between 1980 and 1993, where he headed the European Healthcare practice<ref>http://www.mckinsey.com/client_service/healthcare_systems_and_services {{Webarchive|url=https://web.archive.org/web/20130424150911/http://www.mckinsey.com/client_service/healthcare_systems_and_services |date=2013-04-24 }}</ref> and advised UK, Swiss and US pharmaceutical companies. He also helped establish ']',<ref>{{Cite web|title=London First|url=https://www.londonfirst.co.uk/|access-date=2021-10-05|website=www.londonfirst.co.uk}}</ref> a public/private initiative that aims to enhance London's status as a global city. As General Manager of ]'s healthcare business,<ref>{{Cite web|url=http://www-935.ibm.com/industries/uk/en/healthcare/|title=Healthcare Technology Solutions & Services}}</ref> between 1993 and 1996 he launched ], one of the earliest Internet healthcare applications.<ref></ref> At ],<ref>{{Cite web|url=http://www.nndb.com/company/216/000123844/|title=Chiron Corporation}}</ref> a multinational bio-technology firm that was acquired by ] in 1996, he headed the diagnostics business, which brought the latest ] to market.{{cn|date=May 2022}} He subsequently served as a chairman and chief executive of Molecular Staging,<ref>http://molecularstaging.aussieblogs.com.au {{Webarchive|url=https://web.archive.org/web/20130420114935/http://molecularstaging.aussieblogs.com.au/ |date=2013-04-20 }}</ref> whose ] enables ] on rare ].<ref>http://molecularstaging.aussieblogs.com.au/technology/ {{Webarchive|url=https://web.archive.org/web/20140125225325/http://molecularstaging.aussieblogs.com.au/technology/ |date=2014-01-25 }}</ref>


On returning to the UK, he headed the ] (ABPI) for six years between 2004 and 2011<ref name=PMLive>{{cite web|title=Former ABPI head Richard Barker joins Aegate as senior adviser|date=9 January 2012|url=http://www.pmlive.com/pharma_news/abpi_richard_barker_aegate_michael_peace_355981|publisher=Pmlive.com|accessdate=2013-02-11}}</ref> and initiated policy programs in stratified medicine,<ref>try-info/future/Pages/personalised-medicines.aspx</ref> while also launching frameworks for translational partnerships between academia and industry.<ref>http://www.abpi.org.uk/industry-info/future/Pages/collaboration.aspx {{Webarchive|url=https://web.archive.org/web/20130407085850/http://www.abpi.org.uk/industry-info/future/Pages/collaboration.aspx |date=2013-04-07 }}</ref> He also formed and chaired Stem Cells for Safer Medicines,<ref>http://www.sc4sm.org {{Webarchive|url=https://web.archive.org/web/20220617163230/https://www.sc4sm.org/ |date=2022-06-17 }}</ref> a public/private partnership formed to develop new approaches to testing potential new medicines for toxicity.


==Career==
In 2012 with his colleagues at Oxford and UCL, he founded CASMI to develop, test and promote new models of medical innovation, including adaptive licensing, cell therapy regulation and a combination of therapeutic and diagnostic products to focus treatments on the patients most likely to benefit.<ref>http://www.casmi.org.uk {{Webarchive|url=https://web.archive.org/web/20180625202006/http://casmi.org.uk/ |date=2018-06-25 }}</ref> As Founding Director of CASMI he held an associate professorship in Oxford University's Medical Division from 2012 to 2017.<ref>{{Cite web|title=UCL School of Life and Medical Sciences — CASMI|date=14 August 2018|url=https://www.ucl.ac.uk/school-life-medical-sciences/research/casmi}}</ref>
Barker's career has spanned Europe and the US, including work with ] from 1980 to 1993, where he led the European healthcare practice. He contributed to the founding of ']', a public/private initiative to enhance London's global status. At ], he managed the global healthcare business from 1993 to 1996, launching Health Village, an early Internet healthcare application. He later worked at ], heading the diagnostics business, and served as chairman and CEO of Molecular Staging, focusing on ] amplification technology.


Returning to the UK, Barker led the ] (ABPI)<ref>{{cite web |title=ABPI Honorary Fellows |url=https://www.bps.ac.uk/about/who-we-are/honorary-fellows-directory/profile?ID=762b7f3a-8d90-e611-80d8-00155d146335&product=%7Chonorary |access-date=2024-08-25}}</ref> from 2004 to 2011, supporting initiatives in ] and translational partnerships between academia and industry. He co-founded the ] (CASMI) in 2012 and held an associate professorship at ] until 2017. Barker previously chaired the South London Academic Health Science Network and the charity International Health Partners<ref>{{cite web |title=International Health Partners |url=https://www.ihpuk.org |access-date=2024-08-25}}</ref>.
He chairs the South London Academic Health Science Network,<ref>{{Cite web|url=http://www.kingshealthpartners.org/info/southlondonahsn|title = About Us &#124; King's Health Partners &#124; London}}</ref> which aims to improve the quality and consistency of care in that part of the ] (NHS), and to facilitate innovations emerging from academic and industrial research into NHS application.<ref>{{Cite web|url=https://www.gov.uk/government/publications/academic-health-science-networks-request-for-expressions-of-interest-to-create-ahsns--2|title = &#91;Withdrawn&#93; Academic health science networks: Request for expressions of interest to create AHSNs}}</ref>


Currently, Barker is the chairman and co-founder of Metadvice<ref>{{cite web |title=Metadvice |url=https://www.metadvice.com/ |access-date=2024-08-25}}</ref>, which develops AI-driven healthcare platforms. He is also the founder and chairman of New Medicine Partners<ref>{{cite web |title=New Medicine Partners |url=https://newmedicine.io/ |access-date=2024-08-25}}</ref>, where he advises on ] and health. As a recognized futurist in healthcare, Barker serves as the chair of the advisory board at NWPharmaTech<ref>{{cite web |title=NWPharmaTech |url=https://nwpharmatech.com/ |access-date=2024-08-25}}</ref> and is a co-founder and board member of 2BWell<ref>{{cite web |title=2BWell |url=https://www.2bwell.org/ |access-date=2024-08-25}}</ref>, a mental health chatbot initiative supporting Ukrainians. Additionally, he is a visiting professor in Precision Population Health at ], reflecting his ongoing commitment to advancing healthcare innovation and ].
Effective as of December 18, 2020, he resigned from the Board of Directors of 180 Life Sciences Corp, because of other commitments that would not allow him to spend sufficient time on Company matters. <ref>{{Cite web|title=CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934|url=https://www.sec.gov/Archives/edgar/data/0001690080/000121390020044354/ea132067-8k_180lifescien.htm|access-date=2021-12-16}}</ref>


He chairs the charity International Health Partners that brings donated medicines to developing countries, crisis situations and refugee camps.<ref>{{Cite web|url=http://www.ihpuk.org/our-team/4594052457|title=ABOUT - IHP|website=www.ihpuk.org|language=en|access-date=2018-06-10}}</ref>

He has also founded and directed New Medicine Partners, an advisory company that creates strategies for precision medicine and precision health to advance a healthy lifespan.<ref>{{Cite web|url=https://www.newmedicine.io|title=Welcome to New Medicine Partners|website=New Medicine Partners|language=en-GB|access-date=2018-06-10}}</ref> He is also the Founding Director of ], a global healthcare company developing an AI-driven platform for clinical decision making.<ref>{{Cite web|title=Metadvice :: Team {{!}} Leaders {{!}} Experts|url=https://www.metadvice.com/team3.php|access-date=2021-04-07|website=www.metadvice.com}}</ref>


== Board memberships == == Board memberships ==
Richard Barker is the Founder and Chairman of New Medicine Partners<ref>{{cite web |title=New Medicine Partners |url=https://newmedicine.io/ |access-date=2024-08-25}}</ref>, Co-founder and Chairman of Metadvice<ref>{{cite web |title=Metadvice |url=https://www.metadvice.com/ |access-date=2024-08-25}}</ref>, Chair of the Advisory Board at NWPharmaTech<ref>{{cite web |title=NWPharmaTech |url=https://nwpharmatech.com/ |access-date=2024-08-25}}</ref>, and Co-founder and Board Member of 2BWell<ref>{{cite web |title=2BWell |url=https://www.2bwell.org/ |access-date=2024-08-25}}</ref>. He has previously served as Chairman and CEO of Molecular Staging, chaired the South London Academic Health Science Network, contributed to International Health Partners<ref>{{cite web |title=International Health Partners |url=https://www.ihpuk.org/ |access-date=2024-08-25}}</ref>, and served on the board of Celgene Corporation.
* ]<ref>{{cite web|url=http://www.innovationdebate.com/debate/panelists/dr-richard-barker/ |title=Dr Richard W. Barker: The Innovation Debate 2012 |publisher=Innovationdebate.com |date=2012-11-20 |accessdate=2013-02-19}}</ref>



== Awards == == Awards ==
In 2011 Professor Richard Barker was awarded ] for his services to the ] by the ].<ref>{{Cite web|date=2011-12-30|title=Honours: Order of the British Empire, Civil - OBE|url=https://www.independent.co.uk/news/uk/home-news/honours-order-british-empire-civil-obe-6283146.html|access-date=2021-04-07|website=The Independent|language=en}}</ref> In 2021 he was awarded Honorary Fellowship of the ]. Richard Barker was appointed ] (OBE) in 2011 for his contributions to the ]. In 2021, he was awarded an ] by the ], recognizing his significant impact on the field.



== Published works == == Published works ==
;Books ;Books
* Barker, Richard (2010). ''2030: the Future of Medicine'', Oxford University Press, 118 pages. {{ISBN|978-0199600663}} * Barker, Richard (2010). ''2030: The Future of Medicine'', Oxford University Press, 118 pages. {{ISBN|978-0199600663}}
*Barker, Richard (2016). ''Bioscience — Lost in Translation?,'' Oxford University Press, 226 pages. {{ISBN|978-0198737780}} *Barker, Richard (2016). ''Bioscience — Lost in Translation?,'' Oxford University Press, 226 pages. {{ISBN|978-0198737780}}



;Selected Articles ;Selected Articles
* Barker, Richard W.; and Sarah Garner. "Adaptive drug development and licensing", ''Regulatory Rapporteur'', Vol 9, No 10, page 13, October 2012. * Barker, Richard W.; and Sarah Garner. "Adaptive Drug Development and Licensing", ''Regulatory Rapporteur'', Vol. 9, No. 10, p. 13, October 2012.
* Barker, Richard. "A flexible blueprint for the future of drug development", ''The Lancet'', Volume 375, Issue 9712, pages 357–359, 30 January 2010. * Barker, Richard. "A Flexible Blueprint for the Future of Drug Development", ''The Lancet'', Vol. 375, Issue 9712, pp. 357–359, 30 January 2010.
*See . *See .



==References== ==References==
Line 56: Line 56:
] ]
] ]
]
]
]
]
]
]
]
]
]
]

Revision as of 20:27, 25 August 2024

Healthcare leader and precision medicine expert

Prof. Richard Barker OBE FFPM is a healthcare leader known for his forward-thinking approach and innovative contributions to the field. He co-founded and chairs Metadvice, a company developing AI-driven healthcare platforms. He also established New Medicine Partners and is the Founding Director of the University of Oxford’s Centre for the Advancement of Sustainable Medical Innovation (CASMI) in collaboration with University College London. Barker is the chair of the advisory board at NWPharmaTech and a co-founder and board member of 2BWell, a mental health initiative supporting Ukrainians. Additionally, he is a visiting professor in Precision Population Health at King’s College London.


Prof. Richard Barker
Occupation(s)Healthcare Leader and Precision Medicine and Longevity Expert
Known forFounder of New Medicine Partners, Co-founder of Metadvice, and Founding Director of the University of Oxford’s Centre for Sustainable Medical Innovation. Chair of the Advisory Board at NWPharmaTech and a leader in advancing precision medicine, healthcare innovation, and healthy longevity initiatives.

Early life

Barker was born in South London and attended Alleyn's School in Dulwich, London.


Education

Barker studied chemistry at Exeter College, Oxford, earning a bachelor's degree. He pursued research on the biological applications of magnetic resonance techniques for his PhD in Philosophy at Oxford University, followed by post-doctoral studies in Munich, Germany, and Leeds, England.


Career

Barker's career has spanned Europe and the US, including work with McKinsey & Company from 1980 to 1993, where he led the European healthcare practice. He contributed to the founding of 'London First', a public/private initiative to enhance London's global status. At IBM, he managed the global healthcare business from 1993 to 1996, launching Health Village, an early Internet healthcare application. He later worked at Chiron Corporation, heading the diagnostics business, and served as chairman and CEO of Molecular Staging, focusing on genome amplification technology.

Returning to the UK, Barker led the Association of the British Pharmaceutical Industry (ABPI) from 2004 to 2011, supporting initiatives in stratified medicine and translational partnerships between academia and industry. He co-founded the Centre for the Advancement of Sustainable Medical Innovation (CASMI) in 2012 and held an associate professorship at Oxford University until 2017. Barker previously chaired the South London Academic Health Science Network and the charity International Health Partners.

Currently, Barker is the chairman and co-founder of Metadvice, which develops AI-driven healthcare platforms. He is also the founder and chairman of New Medicine Partners, where he advises on precision medicine and health. As a recognized futurist in healthcare, Barker serves as the chair of the advisory board at NWPharmaTech and is a co-founder and board member of 2BWell, a mental health chatbot initiative supporting Ukrainians. Additionally, he is a visiting professor in Precision Population Health at King's College London, reflecting his ongoing commitment to advancing healthcare innovation and public health.


Board memberships

Richard Barker is the Founder and Chairman of New Medicine Partners, Co-founder and Chairman of Metadvice, Chair of the Advisory Board at NWPharmaTech, and Co-founder and Board Member of 2BWell. He has previously served as Chairman and CEO of Molecular Staging, chaired the South London Academic Health Science Network, contributed to International Health Partners, and served on the board of Celgene Corporation.


Awards

Richard Barker was appointed Officer of the Order of the British Empire (OBE) in 2011 for his contributions to the pharmaceutical industry. In 2021, he was awarded an Honorary Fellowship by the Faculty of Pharmaceutical Medicine, recognizing his significant impact on the field.


Published works

Books
  • Barker, Richard (2010). 2030: The Future of Medicine, Oxford University Press, 118 pages. ISBN 978-0199600663
  • Barker, Richard (2016). Bioscience — Lost in Translation?, Oxford University Press, 226 pages. ISBN 978-0198737780


Selected Articles
  • Barker, Richard W.; and Sarah Garner. "Adaptive Drug Development and Licensing", Regulatory Rapporteur, Vol. 9, No. 10, p. 13, October 2012.
  • Barker, Richard. "A Flexible Blueprint for the Future of Drug Development", The Lancet, Vol. 375, Issue 9712, pp. 357–359, 30 January 2010.
  • See CASMI website.


References

  1. "Metadvice". Retrieved 2024-08-25.
  2. "New Medicine Partners". Retrieved 2024-08-25.
  3. "Dr Richard Barker OBE". CASMI. Archived from the original on 2013-04-23. Retrieved 2013-02-11.
  4. "NWPharmaTech". Retrieved 2024-08-25.
  5. "2BWell". Retrieved 2024-08-25.
  6. "Home - Alleyn's School". www.alleyns.org.uk. Retrieved 2024-08-25.
  7. "Homepage". Exeter College. Retrieved 2024-08-25.
  8. "ABPI Honorary Fellows". Retrieved 2024-08-25.
  9. "International Health Partners". Retrieved 2024-08-25.
  10. "Metadvice". Retrieved 2024-08-25.
  11. "New Medicine Partners". Retrieved 2024-08-25.
  12. "NWPharmaTech". Retrieved 2024-08-25.
  13. "2BWell". Retrieved 2024-08-25.
  14. "New Medicine Partners". Retrieved 2024-08-25.
  15. "Metadvice". Retrieved 2024-08-25.
  16. "NWPharmaTech". Retrieved 2024-08-25.
  17. "2BWell". Retrieved 2024-08-25.
  18. "International Health Partners". Retrieved 2024-08-25.
Categories: